Alpha 2.0
Login Register
» Articles » PMID: 37210081

A Randomized Controlled Trial of Eplerenone in Asymptomatic Phospholamban P.Arg14del Carriers

Overview
Journal Eur Heart J
Publisher Oxford University Press
Specialty Cardiology & Vascular Diseases
Date 2023 May 20
PMID 37210081
Authors
Remco de Brouwer
Wouter P Te Rijdt
Edgar T Hoorntje
Ahmad Amin
Folkert W Asselbergs
Moniek G P J Cox
Jeroen F van der Heijden
Hans Hillege
Jacco C Karper
Belend Mahmoud
Peter van der Meer
Anton Oomen
Anneline S J M Te Riele
Herman H W Sillje
Hanno L Tan
Jan Peter van Tintelen
Dirk J Van Veldhuisen
Berend Daan Westenbrink
Ans C P Wiesfeld
Tineke P Willems
Paul A van der Zwaag
Arthur A M Wilde
Rudolf A de Boer
Maarten P van den Berg
Affiliations
Soon will be listed here.
Citing Articles

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? : Pro: Provide pre-emptive treatment to asymptomatic carriers.

de Boer R Neth Heart J. 2023; 31(7-8):287-288.

PMID: 37493902 PMC: 10400733. DOI: 10.1007/s12471-023-01793-0.

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? : Con: Do no harm to asymptomatic carriers.

Doevendans P Neth Heart J. 2023; 31(7-8):289-290.

PMID: 37491506 PMC: 10400497. DOI: 10.1007/s12471-023-01794-z.

References
1.
Te Rijdt W, Hoorntje E, de Brouwer R, Oomen A, Amin A, Van der Heijden J . Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Neth Heart J. 2021; 30(2):84-95. PMC: 8799798. DOI: 10.1007/s12471-021-01584-5. View
2.
Eijgenraam T, Boogerd C, Stege N, Oliveira Nunes Teixeira V, Dokter M, Schmidt L . Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circ Heart Fail. 2021; 14(11):e008532. PMC: 8589082. DOI: 10.1161/CIRCHEARTFAILURE.121.008532. View
3.
Hansson L, Hedner T, Dahlof B . Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992; 1(2):113-9. DOI: 10.3109/08037059209077502. View
4.
Eijgenraam T, Boukens B, Boogerd C, Schouten E, van de Kolk C, Stege N . The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep. 2020; 10(1):9819. PMC: 7300032. DOI: 10.1038/s41598-020-66656-9. View
5.
Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers J . Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival.... Circulation. 2009; 119(18):2471-9. DOI: 10.1161/CIRCULATIONAHA.108.809194. View